The impact of the CD34+ cell dose on chronic graftversus-host disease (cGVHD) and the clinical outcome was analyzed in 41 consecutive adult patients submitted to allogeneic peripheral blood stem cell transplantation from HLA-identical siblings. The patients were classified into 'low' or 'high' CD34+ cell dose groups based on whether they received less or more than a median CD34+ cell dose of 10.5 Â 10 6 /kg, respectively. There was a significant difference in the incidence of extensive cGVHD (low vs high group, 25.0 vs 66.7%, P ¼ 0.021) and relapse (47.6 vs 20.0%, P ¼ 0.049) between the two groups. With a median follow-up of 335 days, the 3-year survival estimate for the whole population was 47.9%, while that for the low and high groups was 29.9 and 67.8%, respectively (P ¼ 0.0434). An inverse relation was noted between the relapse rate and the incidence of extensive cGVHD (P ¼ 0.043). It would appear reasonable that the optimal dose of CD34+ cells should be determined based on the disease status or aggressiveness of the malignant cells in each patient. Yet, in the case of patients with a high risk of relapse, transplantation with a CD34+ cell dose of 410.5 Â 10 6 /kg would seem to be acceptable to minimize the risk of relapse. Bone Marrow Transplantation (2003) 31, 967-972.
Introduction
Despite conflicting evidence [1] [2] [3] [4] on the impact of the CD34+ cell dose on survival and graft-versus-host disease (GVHD) in allogeneic stem cell transplantation, it is reasonable to believe that the CD34+ cell dose has a positive influence on engraftment and survival. 5, 6 However, a recent study 7 suggested that transplantation with a higher CD34+ cell dose was detrimental in terms of chronic GVHD (cGVHD) in allogeneic CD34+ cell-selected peripheral blood stem cell transplantation (PBSCT). Moreover, this association may also exist in the context of allogeneic unmanipulated PBSCT where a higher T-cell content or extremely high dose of CD34+ cells can be involved. It should be noted that CD34+ cells not only participate in engraftment, but also have an immunogenic role. However, although cGVHD is a leading cause of late mortality in allogeneic settings, it also plays a positive role in preventing relapse, especially in advanced hematological malignancies with a high risk of relapse. Accordingly, to investigate the impact of a high dose of CD34+ cells in allogeneic unmanipulated PBSCT for hematological diseases, the current study analyzed the impact of the CD34+ cell dose on cGVHD and the clinical outcome in 41 consecutive adult patients submitted to allogeneic unmanipulated PBSCT from HLA-identical siblings.
Patients and methods
The current study was performed from September 1998 to April 2002 at a single institution (Kyungpook National University Hospital), and included a total of 41 consecutive adult patients with hematological diseases (21 patients with standard risk and 20 patients with high risk) who received an allogeneic unmanipulated PBSCT from an HLAidentical sibling. The patients' characteristics are summarized in Table 1 . The median age of the patients was 36 years (range, 17-56 years). The male to female ratio was 1.4:1. The enrolled hematological diseases included AML (n ¼ 25), CML (n ¼ 5), MDS (n ¼ 3), NHL (n ¼ 2), and severe aplastic anemia (n ¼ 6). A variety of conditioning regimens (busulfan/cytoxan for AML, CML, and MDS; antithymocyte globulin/cytoxan for severe aplastic anemia; fludarabine-based regimen for malignant lymphoma) were adopted according to the underlying hematological diseases. All patients received unmanipulated PBSCs at day 0 from HLA-matched sibling donors. The patients were classified into low or high CD34+ cell dose groups based on whether they received less or more than a median CD34+ cell dose of 10.5 Â 10 6 /kg, respectively. A comparison of the clinical outcomes between the two groups was performed. Detailed written and informed consent was obtained from all donors and patients before beginning the procedure.
Donor mobilization
The PBSCs were mobilized with 10 mg/kg/day G-CSF (Filgrastim, Leukokine s , CJ, Co., Seoul, Korea) alone (n ¼ 1) or with 10 ug/kg/day GM-CSF (Sargramostim, Leucogen s , LG, CI., Seoul, Korea) alone (n ¼ 6) or with a concurrent regimen (n ¼ 17) with 5 mg/kg/day G-CSF and 5 mg/kg/day GM-CSF for 5 days or with a sequential regimen (n ¼ 17) with GM-CSF alone 10 mg/kg/day for 3 days followed by G-CSF alone 10 mg/kg/day for 2-3 days from HLA-matched sibling donors. The administration of G-and/or GM-CSF was continued and an apheresis repeated every morning until the target number of cells was obtained. The normal healthy donors were asked and agreed to undergo a large volume (15 l) leukapheresis on day 5. A standard 10-l leukapheresis was performed if the donor platelet count was o70 Â 10 9 /l for successive days. The leukapheresis was performed using a Fenwal CS 3000+ s blood cell separator (Baxter, Healthcare, Deerfield, IL, USA) with acid-citrate-dextrose as the anticoagulant. Venous access was obtained by venipuncture of the femoral vein. For successful transplantation, the minimum target number of MNCs and CD34+ cells was 43 Â 10 8 /kg and 43 Â 10 6 /kg, respectively. We planned to harvest as many stem cells as possible from donors to fully take the advantage of allogeneic PBSCT. If harvesting CD34+ cells of 43 Â 10 6 /kg was not achieved from the donor, the patient was transplanted with bone marrow cells harvested from the same donor who manifested a mobilization failure. The PBSC products were infused fresh and unmanipulated. Detailed data on harvesting according to three different mobilization regimens were reported previously. 8 
Graft-versus-host disease prophylaxis
The prophylaxis against acute GVHD (aGVHD) consisted of methotrexate (MTX) and cyclosporin A (CyA). All patients were scheduled to receive MTX 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6, and 11. CyA was administered intravenously at a dose of 2.5-5 mg/kg/day starting on the day before the PBSCT. Oral CyA, 6 mg/kg/day, was substituted for intravenous administration when tolerated. Starting on day 60, the oral CyA administration was diminished 5% weekly, then maintained at a dose of 1.5 mg/kg/day until day 270 for patients without symptomatic cGVHD. A flat CyA dose of 75 mg/day was continuously administered to prevent the flare-up of cGVHD in patients with a history of symptomatic extensive cGVHD until at least 2 years after day 270. After 2 years, if the patient did not manifest cGVHD symptoms and laboratory abnormalities, CyA was discontinued within 3 months. The doses of CyA were adjusted if necessary and the last dose of MTX was skipped for patients with severe mucositis or an impaired renal function. Acute and chronic GVHD were diagnosed and graded using established criteria. 9 
Supportive care
All patients were nursed in isolation rooms with laminar airflow systems. Prophylaxis was employed for Pneumocystis carinii (trimethoprim/sulfamethoxazole, 160 mg/800 mg p.o. twice a week from day À6 to day À2 and from day +20 to day +180 post-transplantation) and the herpes simplex virus (acyclovir 250 mg/m 2 i.v. or p.o. from day 0 to day +120). Fluconazole (100 mg q.d.) was administered as a fungal prophylaxis from day À6 to day +75. Oral norfloxacin (400 mg b.i.d.) was administered from day À6 to day +20. GM-CSF (at a dose of 6 mg/kg/day) was given to all patients from day 1 postinfusion until granulocyte recovery. Blood products were infused for hematocrit o25% and/or platelet counts o20 Â 10 9 /l. All hemo-derived transfusion products were irradiated prior to use.
Definitions
The day of the stem cell infusion was defined as day 0. WBC engraftment was defined as the number of days taken to achieve an ANC 40.5 Â 10 9 /l for three consecutive days. Platelet engraftment was defined as the time taken to achieve platelets 420 Â 10 9 /l without requiring transfusion. cGVHD was defined as the presence of GVHD after day 90. Skin biopsies were taken from all patients with skin rashes. Survival was determined based on the time from the transplantation until death from any cause. Standard risk diseases were defined as hematological malignancies in acute leukemia or aggressive lymphoma of first complete remission or CML in the chronic phase or severe aplastic anemia patients with a history of transfusion of no more than 50 units of packed RBC or whose disease history was less than 5 years.
Results

Transplantation data
The clinical outcomes are summarized in Table 2 . The median dose of CD34+, CD3+ cells, and MNC infused /kg), respectively. The median time taken for the ANC and platelets to reach 500 and 20 000 Â 10 6 /ml was 16 days (range, 11-26 days) and 17 days (range, 9-56 days), respectively. The occurrence of febrile episodes was 87.8%. CMV antigenemia appeared in 13 patients (31.7%). A total of 30 patients (73.2%) experienced aGVHD over grade 1. Extensive cGVHD was encountered in 17 patients (41.5%). Relapse and death occurred in 14 (34.1%) and 17 patients (41.5%), respectively, when last assessed (median follow-up duration, 335 days; range, 69-1263 days). The causes of death included relapse (n ¼ 9), sepsis (n ¼ 6), and cGVHD-related death (n ¼ 2). There was no significant correlation between the number of CD34+ cells and WBC (P ¼ 0.193) or platelet (P ¼ 0.760) engraftment day.
Comparison of clinical outcomes between 'low' and 'high' CD34 cell dose groups (Table 3) The median age of the 'low' (n ¼ 21) and 'high' (n ¼ 20) CD34+ cell dose groups was 36 years (P ¼ NS). There was no difference in the sex distribution or disease distribution between the two groups. The low CD34+ cell dose group included 10 standard-risk and 11 high-risk patients: AML (n ¼ 11), CML (n ¼ 3), MDS (n ¼ 2), NHL (n ¼ 1) and severe aplastic anemia (n ¼ 4). The high CD34+ cell dose group included 11 standard-risk and nine highrisk patients; AML (n ¼ 14), CML (n ¼ 2), MDS (n ¼ 1), NHL (n ¼ 1), and severe aplastic anemia (n ¼ 2). The median infused MNC and CD3+ cell count was 6.50 Â 10 8 /kg for the high group, respectively. Although a higher incidence of aGVHD was observed in the high CD34+ cell dose group, the difference was not statistically significant. Conversely, there was a difference in the incidence of extensive cGVHD (low vs high group, 25.0 vs 66.7%) and relapse (low vs high group, 47.6 vs 20.0%) between the two groups, and increased CD34+ cell dose was statistically significantly associated with an increased hazard of extensive cGVHD (P ¼ 0.038, continuous CD34+ cell dose) and decreased relapse (P ¼ 0.046, continuous CD34+ cell dose) in the likelihood-ratio test for Cox model. With a median follow-up of 335 days (range, 69-1263 days), 24 patients survived. The estimated 3-year survival rate for the whole population was 47.9%. Figure 1 shows Kaplan-Meier survival curves according to the infused CD34+ cell dose. The estimated 3-year survival rates for the low and high groups were 29.9 and 67.8%, respectively (P ¼ 0.0434).
Relation between extensive cGVHD and relapse
An inverse relation was observed between the relapse rate and the incidence of extensive cGVHD (P ¼ 0.043). Among the nonrelapsed and relapsed patients, the incidence of extensive cGVHD was 58.3 and 21.4%, respectively. Among 17 patients with extensive cGVHD, only three patients (17.6%) experienced relapse.
Discussion
There is conflicting evidence on the relapse rate relative to the stem cell dose. Several groups [10] [11] [12] advocate that the relapse rate is lower in recipients who receive a higher stem cell dose or PBSC than in patients who receive a lower stem cell dose or bone marrow cells for allogeneic SCT. This lower relapse rate could be explained by the so-called 'stem cell competition effect', where, after transplantation, residual clonogenic tumor cells are displaced by rapidly expanding normal stem cells, thereby representing another possible graft-vs-leukemia (GVL) effect as distinct from GVHD. 10 However, the long-term negative effects of high numbers of CD34+ cells in an allogeneic SCT setting have recently been questioned. Urbano-Ispizua et al 7 suggested that higher CD34+ cell doses (43 Â 10 6 /kg) may be associated with a higher transplant-related mortality (TRM) than a lower dose (1-3 Â 10 6 /kg) in allogeneic CD34+ cell-selected PBSCT from HLA-identical sibling donors. In their study, patients who received a higher CD34+ cell dose had a higher incidence and earlier appearance of GVHD, which is associated with an increased TRM because of severe infections. Their explanation for the detrimental effect of infusing high numbers of CD34+ cells is that CD34+ cells do not simply participate in engraftment, but also have an immunologic role in inducing GVHD in allogeneic SCT. As such, GVHD is exacerbated by the cytokines released from the rapidly expanding myeloid population because of the precipitated engraftment resulting from a high CD34+ cell dose. It has already been observed that early engraftment independently predicted the development of aGVHD after allogeneic SCT, which eventually progressed to cGVHD. 13, 14 However, no significant association between aGVHD and the CD34+ cell dose has been observed in any other studies. 5, 11, 15 In the current study, a higher incidence of aGVHD was found in the high CD34+ cell dose group, yet it was not statistically significant.
Concerning an adequate range for the CD34+ cell dose in allogeneic unmanipulated PBSCT, the importance of the CMV, cytomegalovirus; GVHD, graft-versus-host disease.
CD34 þ cell dose in allogeneic PBSCT SK Sohn et al CD34+ cell dose has already been clearly demonstrated in an allogeneic BMT or T-cell-depleted PBSCT setting. 6, 7 However, the clinical relevance of the number of CD34+ cells from bone marrow differs from that from PBSCT. Although a higher dose of CD34+ cells produces better clinical results in allogeneic BMT settings, 5,16 the same results cannot be assumed with allogeneic unmanipulated PBSCT because of the higher incidence of life-threatening extensive cGVHD. 4 Median allogeneic PBSC doses of 6.7 Â 10 6 CD34+ cells/kg, 13.1 Â 10 6 CD34+ cells/kg, and 10.7 Â 10 6 CD34+ cells/kg were successfully transplanted in previous studies by Schmitz et al, 17 Bensinger et al, 18 and Korbling et al, 19 respectively. In these studies, hematologic recovery was generally rapid, and higher CD34+ cell doses resulted in more rapid engraftment. However, it is impossible to define the optimal CD34+ cell dose for allogeneic PBSCT because published data show conflicting results on the survival rate and incidence of cGVHD. Zaucha et al 13 observed that higher doses of CD34+ cells (48.0 Â 10 6 /kg) were associated with a significantly increased risk of extensive cGVHD (HR ¼ 2.3%, 95% confidence interval 1.4-3.7, P ¼ 0.001), rather than a demonstrable impact on survival and relapse. Yet, their results differ from previously published studies 10, 20 that report on an inverse association between cGVHD and the risk of relapse, suggesting that the GVL effect carried by allogeneic PBSC grafts is not further improved when clinical symptoms of extensive cGVHD develop. A study 21 conducted by the International Bone Marrow Transplant Registry also inferred that the increased severity of chronic GVHD was not linked to a reduced risk of relapse among HLA-identical siblings receiving conventional stem cell transplantations. Przepiorka et al 4 reported that there was a trend for increasing cGVHD in the higher CD34+ cell dose group and patients who developed extensive cGVHD Table 3 Comparison of clinical outcomes between 'low' and 'high' CD34 cell dose groups CD34 þ cell dose in allogeneic PBSCT SK Sohn et al had a relatively short progression-free survival because of a relatively high GVHD-related mortality. However, according to Ringden et al's 22 recent study 22 , a higher CD34+ cell dose than a median of 6.0 Â 10 6 /kg was associated with an improved leukemia-free survival rate in recipients of HLAidentical sibling PBSCT. In the current study, which compared the impact of 'high' and 'low' CD34+ cell doses, a higher CD34+ cell dose above a median of 10.5 Â 10 6 /kg exhibited a statistically significant association with an increased risk of extensive cGVHD. However, a significantly lower relapse rate and improved survival were observed in the high CD34+ cell dose group. This clear inverse relation may have been because of the relatively high number of patients with advanced hematological diseases included in the study. The current results also contradict Urbano-Ispizua's finding 7 of a similar relapse rate between high (43.0 Â 10 6 CD34+ cells/kg) and low (1.0-3.0 Â 10 6 CD34+ cells/kg) CD34+ doses in a T-cell-depleted setting. However, in their study, the impact of the CD34+ dose on the relapse rate in a Tcell-depleted setting was possibly obscured because the incidence of extensive cGVHD was found to be negligible in allogeneic T-cell-depleted PBSCT and no difference was observed between the high and low CD34+ cell dose groups.
Each transplantation center needs to have its own critical cut-off CD34+ cell dose because the techniques used to measure CD34+ cell numbers vary between centers. In addition, it may also be reasonable to determine the CD34+ cell dose for a patient based on the disease status or aggressiveness of the disease, as well as the selected preparation regimen including a GVHD prophylaxis. For example, in the case of patients with a standard risk of relapse, the determination of the CD34+ cell dose may be very important for successful transplantation through minimizing the TRM because of cGVHD. As such, avoiding infusion with an extremely high dose of CD34+ cells would appear to be a reasonable strategy for patients with a standard risk of relapse.
In a previous study, 10 cGVHD was associated with a decreased risk of relapse and no significant increase in deaths in complete remission, thereby leading to an increased duration of both disease-free survival and overall survival through the induction of a strong GVL effect in patients with advanced leukemia. Intentional cGVHD or a GVL effect is needed in specific clinical situations where standard allogeneic transplantation by itself does not lead to good survival, such as high-risk ALL (pre-B ALL or Philadelphia chromosome positive ALL), primary refractory leukemia, or CML in blastic crisis. 23 Brunet et al 10 suggested that the use of allogeneic PBSC, which contains 2-4 times more CD34+ cells than bone marrow, may be preferable in advanced hematological malignancies as the source of stem cells. Based on the current study, for patients with a high risk of relapse, transplantation with a CD34+ cell dose of 410.5 Â 10 6 /kg would appear to be acceptable to minimize the relapse risk by inducing a potent graft-versus-disease effect. However, vigilance as regards extensive cGVHD is necessary to reduce the TRM. The addition of antithymocyte globulin (ATG) to the conditioning regimen may be useful for patients who need to receive a high dose of CD34+ cells, 24 as ATG is known to play a role in preventing GVHD.
In conclusion, a higher incidence of extensive cGVHD and lower relapse rate were observed in the 'high' CD34+ cell dose group compared with the 'low' CD34+ cell dose group. Accordingly, in terms of the immunologic aspects of CD34+ cells, it is reasonable that the decision on the optimal dose of CD34+ cells should be based on the disease status or aggressiveness of the malignant cells in each patient. Further study is required to define the negative impact of a high CD34+ cell dose on long-term morbidity and mortality, and the positive impact of a high CD34+ cell dose on reduced disease relapse in an allogeneic PBSCT setting.
